Clinical Trial

ARC-IM System to Manage Symptomatic Blood Pressure Instability Secondary to Chronic Spinal Cord Injury

Study acronym: Empower BP
Recruiting
View on ClinicalTrials.gov →
Summary
Empower BP is a pivotal, interventional, multicenter, prospective, randomized, controlled double-blinded study to evaluate the safety and effectiveness of the ARC-IM System in managing symptomatic blood pressure instability in individuals with chronic SCI (\>1 year after SCI). The primary effectiveness outcome will be evaluated through subject-reported ADFSCI and seated blood pressure assessments at 3 months post-implant. Following a baseline screening period and the surgical implantation of the ARC-IM System, subjects will be randomized with a 2:1 ratio into an active or control arm for 3 months. All the subjects will undergo therapy activation sessions (into either Group 1: active intervention, or Group 2: intervention aimed to mimic the active intervention without the active component) within 21 days of the surgical implant and will then commence independent at-home use of ARC-IM Therapy. At the 3 Month timepoint, after all assessments are conducted, all subjects will transition to the open-label period in order to receive the active version of the ARC-IM System in an open-label fashion. All subjects will undergo therapy programming sessions following Month 3.
Protocol Amendment History 1 change
notable Trial sites expanded: 5 -> 9 locations 2026-04-29
Trial Details
NCT Number NCT07147296
Lead Sponsor ONWARD Medical, Inc.
Conditions Spinal Cord Injuries, Blood Pressure Disorders
Enrollment 60 participants
Start Date 2025-10-17
Primary Completion 2026-11 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2026-06-16